Session » Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

Date: Monday, November 11, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1012

Apremilast Inhibits Immune Cells Support of Inflammatory Osteoclastogenesis

9:00AM-11:00AM: Abstract Number: 1002

Beneficial Effect of Angiotensin Receptor Blocker in a Spondyloarthritis Animal Model

9:00AM-11:00AM: Abstract Number: 1008

C-X-C Motif Chemokine 10 (CXCL10) as a Transcriptomic Biomarker of Psoriatic Arthritis Susceptibility

9:00AM-11:00AM: Abstract Number: 1013

Effects of Anti-TNF on MiR Expression in Monocytes and CD4+ T-Lymphocytes in Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1004

Genetic Ablation of γδTCR Inhibits IL-23-induced Neutrophilia and Attenuates Epidermal Hyperplasia, Synovitis, Onycholysis and Enthesitis Associated with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1010

IL-17A Induces Distinct Functional Differences Between Two Novel Mesenchymal Stem Cell Populations Identified at the Human Enthesis

9:00AM-11:00AM: Abstract Number: 1007

Memory ex-Th17 Cells Contribute to Synovial Inflammation in Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1009

PDE4 Inhibition Could Improve Endothelial and Adipose Tissue Dysfunction Associated with Psoriatic Arthritis, Key Processes in Cardiovascular Disease

9:00AM-11:00AM: Abstract Number: 1014

Regulatory Role of IL-23 and Its Receptor System in Spondyloarthritis and Its Therapeutic Relevance in anti-IL-17 Failure Patients

9:00AM-11:00AM: Abstract Number: 1011

Single Cell RNA Sequencing of Patients with Psoriatic Disease

9:00AM-11:00AM: Abstract Number: 1005

Tendon T-cell Interactions as Drivers of Chronicity in Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1003

TNF Inhibitors Improves Arterial Stiffness with Cs DMARDs-resistant Active Psoriatic Arthritis: A Cohort Extended Study

9:00AM-11:00AM: Abstract Number: 1006

Vaspin rs35262691 Is Associated with Atherosclerotic Disease in Axial Spondyloarthritis Patients

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].